Fundraising FoxSamsara BioCapital — 2025 Investments
6 investments dated 2025 · listed companies and verified rows first · show all
Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.
BiotechHealthtechNewton, US
Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Founder)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)
Board seatMichael Dybbs· per SEC Form D
Co-investorsBain Capital Life SciencesNew Enterprise Associates (NEA)RA CapitalSanofi VenturesMass General Brigham VenturesREDMILE+9 more
Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets.
BiotechDeep TechSan Diego, US
Sergio Duron(Co-Founder & Chief Executive Officer)inSanford Madigan(Co-Founder, President & Chief Business Officer)inAnaleah Heidt(Chief Scientific Officer)in
BoardJay Lichter(Director)inTighe Reardon(Executive Officer)
Board seatMarcos Milla· per SEC Form D
Co-investorsFrazier Life SciencesLightspeed Venture PartnersAvalon BioVenturesPappas CapitalPfizer Venture InvestmentsJ.P. Morgan Asset Management+1 more
Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance.
BiotechHealthtech
Rachel Humphrey(Founding Chief Executive Officer)inLieping Chen(Scientific Founder)Mitchell Keegan(Chief Development Officer)inWilliam LaRochelle(Chief Scientific Officer)inStacy M. Plum(Chief Technology Officer)
Co-investorsSanofi VenturesTaiho Ventures, LLCPfizer VenturesCanaan PartnersConnecticut InnovationsOUP (Osage University Partners)+6 more
PsiThera is a biotechnology company using computational and physics-based methods—including quantum mechanics, molecular dynamics, machine learning, and simulation—for mechanism-driven drug design and discovery.
AI & Machine LearningBiotechDeep Tech
Co-investorsLightstone Ventures
DELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesBaltimore, US
Victor Velculescu(Founder)inPeter Bach(Executive Officer)Jennifer Buechel(Executive Officer)Douglas Schenkel(Executive Officer)Nicholas Dracopoli(Executive Officer)inSusan Tousi(Chief Executive Officer)in
Board seatMichael Dybbs· per SEC Form D
Co-investorsAV8 VenturesForesite CapitalIllumina VenturesInitiate Venture PartnersMenlo VenturesMerck Global Health Innovation Fund+7 more
Lumen Bioscience develops orally and intranasally delivered biologic drugs and protein-based nutrition products using genetically engineered spirulina algae to express therapeutic proteins such as antibodies, enzymes, and cytokines.
BiotechDeep TechHealthtechSeattle, US
Erik Anderson(Director)Mark Litton(Director)Robert Carlson(Director)Craig Behnke(Executive Officer)Ed Schlect(Director)John Morrow(Executive Officer)
Board seatMarcos Milla· per SEC Form D · $23M raise · filed Apr 2025
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.